What are the opening hours?

Monday 9am - 5pm Tuesday 9am - 5pm Wednesday 9am - 5pm Thursday 9am - 5pm Friday 9am - 5pm

EasyM

EasyM is a blood-based test for Multiple Myeloma minimal residual disease (MRD). The test is CLIA accredited, and not yet FDA approved.

03/16/2026

🩸 Who is at higher risk for multiple myeloma?

• Adults over 60
• Individuals of African Ancestry
• Men (slightly higher risk than women)
• People with a family history of blood cancers
• Those diagnosed with MGUS (a precursor condition)

Understanding these risk factors helps us advocate for earlier testing and monitoring, because knowledge is power. 💪

03/10/2026

🚨 Important news for Canadians living with multiple myeloma 🚨

For the first time, minimal residual disease (MRD) testing for multiple myeloma can be offered in Canada by a Canadian company for Canadian patients.

Rapid Novor’s EasyM® MRD blood test has received a provisional license from the Ontario Ministry of Health, allowing doctors to monitor the disease using a simple blood draw instead of repeated bone marrow biopsies.

Why this is important for patients:
• No painful bone marrow procedures
• Allows more frequent monitoring of the disease
• Can detect disease outside the bone marrow
• Easier testing logistics and more collection sites
• Better access for patients in rural and underserved communities

This is an important step toward improving how multiple myeloma is monitored across Canada.

🔗 Read the full announcement: https://www.easym.com/rapid-novors-blood-test-for-multiple-myeloma-mrd-monitoring-receives-moh-provisional-license/

03/07/2026

Know the CRAB symptoms of multiple myeloma:

🦀 C - Calcium elevation (high calcium levels)
🦀 R - Renal (kidney) problems
🦀 A - Anemia
🦀 B - Bone pain or bone damage

Learn more here: https://www.easym.com/types-of-multiple-myeloma/

Awareness saves lives 💛 Share to help spread awareness!

03/05/2026

What is Multiple Myeloma?

Multiple myeloma is a cancer of plasma cells, a type of white blood cell found in the bone marrow. When these cells become cancerous, they multiply uncontrollably, crowding out healthy blood cells and weakening the body’s ability to fight infection.

Myeloma cells can also cause bone damage and produce an abnormal protein called monoclonal protein (M-protein), which can harm the kidneys and interfere with normal immune function.

Early awareness can make a difference.

Learn the signs. Share the facts. 💛

Learn more here: https://www.easym.com/m-spike-and-multiple-myeloma/

03/03/2026

Myeloma Awareness Month is here 📣

This month, we’ll be sharing important myeloma facts to help raise awareness and support those affected by this cancer.

Follow along all month as we highlight key information and resources. Together, we can spread knowledge and hope 💪

02/28/2026

Frequently Asked Question: Blood Tests for Multiple Myeloma

💡What’s the difference between Clonotypic Mass Spectrometry and Blood-based Next Generation Sequencing (NGS)/Next Generation Flow (NGF)?

Clonotypic Mass Spec: Detects the abnormal protein (M-protein) myeloma cells make. Can find disease even if it’s hidden in the bone marrow or elsewhere.

Blood-based NGS/NGF: Detects cancer cells in circulating blood. Misses disease that is confined to the bone marrow, since myeloma cells don’t always enter the blood.

02/26/2026

How well does clonotypic mass spectrometry (CT-MS) align with next-generation flow (NGF) for measuring minimal residual disease (MRD) in multiple myeloma (MM)?

In Haematologica (Zhao et al., 2024), CT-MS blood-based MRD test was compared directly with EuroFlow (NGF) bone marrow-based MRD test.

Key findings:
• Blood-based CT-MS showed higher sensitivity than bone marrow/based EuroFlow (NGF)
• Rising CT-MS levels predicted relapse, up to 38 months earlier in some patients.
• Overall agreement was 72%, but MS+/NGF− discordance increased with deeper responses.
• CT-MS shows promise for non-invasive, sequential MRD monitoring in MM.

These results support an important concept: MRD assessment may not need to be confined to bone marrow.

Read the full study here: https://easym.com/comparison-of-easym-and-euroflow-mrd/

02/24/2026

Beyond CR: What the Data Means for Patients

Reaching Complete Response (CR) or very good partial response (VGPR) is a big milestone, but it doesn’t always tell the full story. Some patients in CR can still experience a relapse months or years later.

A recent study shows that EasyM can:
- Detect tiny traces of disease that standard tests might miss
- Provide earlier insights on how your treatment is working
- Reveal meaningful differences in response even when CR looks the same for everyone

In other words, the data suggest EasyM could give patients and doctors a more detailed, timely picture of remission and risk, helping inform care decisions sooner.

📖 Read the full study here: https://pubmed.ncbi.nlm.nih

For information on how to access EasyM email myeloma@easym.com

02/21/2026

Derman & Yee on the Future of Myeloma Monitoring 📰

According to Dr. BenDerman (University of Chicago) and Dr. Andrew Yee (Harvard Medical School), clonotypic mass spectrometry (CT-MS) advancing the monitoring of multiple myeloma:

- CT-MS is up to 1,000× more sensitive than traditional SPEP/IFX

- Detects minimal residual disease (MRD) in blood without bone marrow biopsies

- Finds relapse months to years earlier than conventional tests

- Tracks patient-specific monoclonal proteins for precise monitoring

The authors note that CT-MS is now commercially available and can be used for prognostic and monitoring purposes.

Read the full publication here: https://www.sciencedirect.com/science/article/pii/S2473952925005543

02/20/2026

🚨 New Research Update

Oren Pasvolsky and colleagues at MD Anderson Cancer Center are studying EasyM, a blood-based minimal residual disease (MRD) test, in patients with multiple myeloma treated with CAR-T cell therapy.

Key Insight: In this study, EasyM detected disease recurrence more than 8 months before standard testing in one patient, suggesting it may help identify relapse earlier.

💡 Why it matters: Earlier detection after CAR-T therapy could help clinicians monitor patients more closely and make timely treatment decisions.

🔗 Read the abstract here: https://www.sciencedirect.com/science/article/abs/pii/S2666636725022511

02/14/2026

🌟 EasyM Team Spotlight: Yenis Barrios, Lab Operations Specialist 🌟

We’re proud to shine the spotlight on Yenis, our dedicated Lab Operations Specialist at EasyM!

Yenis is passionate about ensuring our laboratory runs smoothly and efficiently so that every test is handled with care, accuracy, and deep respect for the people behind it. She is committed to using our resources wisely while maintaining the highest standards of quality, because she knows that reliable results truly matter when it comes to a patient’s health. Her thoughtful approach and operational excellence help power the critical work we do each day.

A few facts about Yenis:
• She is driven by continuous improvement, always looking for ways to strengthen processes, enhance efficiency, and ensure everything in the lab runs exactly as it should.
• Outside of work, Yenis is a proud mom raising curious, Latin speaking, instrument playing children. Her family is her constant source of motivation. She cherishes simple moments like playing ping-pong, cooking together, and teaching her children responsibility, independence, and care for others. Values that strongly influence how she approaches her work.
• What motivates her daily is the balance of managing both home and lab life. She thrives on the challenges of improving systems and ensuring excellence, knowing that the work we do directly supports patient care and wellbeing.

We’re grateful for Yenis’s dedication, heart, and leadership, and for the pride she brings to supporting our mission every single day.

02/11/2026

Could blood-based MRD testing help give multiple myeloma patients a break from treatment?

A recent review by Paiva et al. in Nature Reviews Clinical Oncology suggests it might be possible.

By combining bone marrow and blood tests for measurable residual disease (MRD), doctors can monitor patients more frequently and closely. This frequent monitoring helps identify patients with deep, sustained remission and could give both doctors and patients the confidence to safely consider treatment free periods.

Why this matters:
- Reduces side effects from ongoing treatment
- Improves quality of life
- Helps doctors track disease better and respond quickly if it returns

Frequent blood based MRD testing could make living with multiple myeloma less burdensome, while maintaining careful, personalized oversight.

Learn more: https://www.easym.com/review-mrd-clinical-management-multiple-myeloma/

Address

EasyM C/o Rapid Novor Inc. , Unit 450, 137 Glasgow Street
Kitchener, ON
N2G4X8

Opening Hours

Monday	9am - 5pm
Tuesday	9am - 5pm
Wednesday	9am - 5pm
Thursday	9am - 5pm
Friday	9am - 5pm

Telephone

+18558999990

Website

http://www.easym.com/

Alerts

Be the first to know and let us send you an email when EasyM posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to EasyM:

Shortcuts

Address
Telephone
Opening Hours
Alerts
Contact The Practice
Claim ownership or report listing

Want your practice to be the top-listed Clinic in Kitchener?